Editorial and medical review
ALUKARD's editorial and medical review process: who writes, who reviews, how often we update, the citation standards we hold ourselves to, and what disqualifies a source from ever being cited.
How ALUKARD sources evidence
The six-step review process
Every new page starts with a brief that names the decision the reader is trying to make, the evidence base we are citing, the contraindications that must be spelled out, and the regulatory guardrails we cannot cross (e.g. off-label claims, same-day Rx).
Writers have at least five years of clinical-content experience and follow ALUKARD's editorial standards (plain language at a ~10th-grade reading level, structured Q&A for snippets, numbered inline citations, TL;DR on every clinical page).
A board-certified clinician - internal medicine, OB-GYN, or obesity medicine depending on topic - reviews the draft against primary sources, annotates inaccuracies, and signs off with a date. The reviewer's name, NPI, and ORCID appear on the byline.
Pages that touch prescription pathways, FDA-regulated compounds, or clinical claims are reviewed against current FDA labeling, DEA restrictions, and state compounding rules. Availability wording is confirmed per-state before publish.
Pillar and compare pages are re-reviewed every 6 months at minimum. Learn articles follow a 9-12 month cycle. Any page gets an immediate out-of-cycle review on new trial publication, FDA label change, professional-society guideline update, or safety signal.
Every page links to a corrections inbox. Reader-submitted inaccuracies are triaged within 5 business days and, if substantiated, produce a dated update note on the page plus a fresh reviewer sign-off.
Citation standards
Every numbered citation on an ALUKARD page is assigned a tier. Tier 1 and tier 2 sources can stand on their own. Tier 3 is labeled as preliminary in-line. Anything outside this list doesn't get cited, period.
Peer-reviewed randomized controlled trials, meta-analyses of RCTs, Cochrane systematic reviews, and registrational trials (SURMOUNT, STEP, SURPASS, SUSTAIN, STRIDE, HERS, etc.).
Clinical practice guidelines from named professional societies (AHA, ACC, ACOG, ES, ADA, AACE, USPSTF). Large prospective cohort studies. Regulatory agency labeling (FDA, EMA) and drug monographs (DrugBank, NIH DailyMed).
Observational studies, pilot trials, and animal-model or mechanistic data. Only cited when clearly labeled as preliminary, and only when a tier 1 or tier 2 source does not exist.
Podcast episodes, company white papers without underlying data, supplement industry case studies, non-peer-reviewed preprints without critical context, 'influencer' claims, and any source that can't be linked to a stable URL or DOI.
Reviewers
Every reviewer on ALUKARD is a board-certified U.S. physician with verifiable credentials. Bio pages link the NPI registry, ORCID, and PubMed bibliography directly, so nothing on this site depends on a stock photo or a claimed credential.
Medical Director
Internal medicine and preventive-care physician overseeing ALUKARD's clinical standards, lab interpretation, and provider-review protocols.
View verifiable bio
OB-GYN, Women's Health Lead
Board-certified OB-GYN focused on menopause, perimenopause, and cycle-aware hormone care for ALUKARD's women's pathways.
View verifiable bio
Metabolic + Men's Health Lead
Family medicine physician board-certified in obesity medicine; oversees GLP-1, tirzepatide, TRT, and peptide review at ALUKARD.
View verifiable bioQuick-reference table
Editorial FAQ
Clinical pages are written by trained health writers with at least five years of experience in the category. Every page is then medically reviewed by a licensed physician on the ALUKARD clinical team before it publishes. Writer and reviewer are both named on the byline.
Reviewers are board-certified U.S. physicians: internal medicine, OB-GYN, and obesity medicine across the topics we cover. Every reviewer's NPI number, state license list, ORCID, and PubMed bibliography is linked on their public bio at alukard.health/team.
Pillar, compare, and product pages are re-reviewed at least every 6 months. Learn articles run on a 9-12 month cycle. Any page is re-reviewed out of cycle when a new FDA label, major RCT, or professional-society guideline changes the recommendation.
Primary evidence comes from peer-reviewed RCTs, systematic reviews, and clinical practice guidelines (AHA, ACC, ACOG, ADA, ES, AACE, USPSTF). Regulatory labeling (FDA, EMA) backs every drug claim. Observational or mechanistic data is cited sparingly and always labeled as preliminary.
ALUKARD sells some of the products it describes (labs, foundational supplements, and provider-reviewed Rx pathways). That is disclosed upfront. Clinical reviewers are paid for review time and do not own equity in product suppliers or pharmaceutical manufacturers.
Every page links to a corrections inbox. We triage reader-submitted corrections within 5 business days. If substantiated, the page gets an updated dated review note, a fresh reviewer sign-off, and - where relevant - a visible correction line at the top of the page.
No. Editorial content is educational. Medical decisions at ALUKARD require intake, eligibility screening, and a licensed provider's sign-off - not a blog post. Readers with urgent or emergency symptoms should contact local emergency services, not the ALUKARD editorial surface.
Writers may use AI tools for research and drafting support. Every sentence in a clinical page is nevertheless reviewed by a named human health writer and countersigned by a licensed clinician reviewer. AI output is not published without human editorial and medical review.
Found a mistake?
If a claim on ALUKARD doesn't match the primary source, send us the citation and the line number. We triage every correction within five business days.
Email corrections@alukard.health